PDCD1 and non-small cell lung carcinoma: Additionally, the combination of ipilimumab (anti–CTLA‐4) and nivolumab (anti‐PD‐1), with or without chemotherapy, has received approval for the treatment of advanced NSCLC across histologic subtypes [65, 66].